Navigation Links
3SBio Inc. Announces Unaudited Fourth Quarter and Fiscal Year 2007 Results
Date:2/20/2008

- Q4 2007 net revenues grew 29.8%, as compared to Q4 2006, to RMB45.7

million (US$6.3 million)

- Q4 2007 net income grew 152.2%, as compared to Q4 2006, to RMB17.9

million (US$2.5 million) - 2007 fiscal year net revenues increased 41.0% year-over-year to RMB180.2

million (US$24.7 million) - 2007 fiscal year net income grew 167.4% year-over-year to RMB81.5 million

(US$11.2 million)

SHENYANG, China, Feb. 20 /Xinhua-PRNewswire-FirstCall/ -- 3SBio Inc. (Nasdaq: SSRX) (''3SBio'' or ''the Company''), a leading China-based biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products, today announced its unaudited financial results for the fourth quarter and fiscal year ended December 31, 2007.

Fourth Quarter 2007 Financial Highlights:

-- Total net revenues increased 29.8% over the fourth quarter 2006 to

RMB45.7 million (US$6.3 million).

-- Net revenue from our flagship injectable recombinant human

erythropoietin products, or EPO products, marketed under our EPIAO

brand, increased 14.7% over the fourth quarter 2006 to RMB29.8 million

(US$4.1 million).

-- Net revenue from our protein-based therapeutic recombinant human

thrombopoietin products, or TPO products, marketed under our TPIAO

brand, increased 99.3% over the fourth quarter 2006 to RMB11.7 million

(US$1.6 million).

-- Operating income decreased 29.6% compared to the fourth quarter 2006

to RMB6.1 million (US$0.8 million)

-- Net income increased 152.2% over the fourth quarter 2006 to RMB17.9

mi
'/>"/>

SOURCE 3SBio Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16

Related biology technology :

1. 3SBio Inc. Announces Change to the Board of Directors
2. 3SBio Inc. Schedules 2007 Fourth Quarter and Full Year Earnings Release on Wednesday, February 20, 2008
3. 3SBio Inc. to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference
4. 3SBio Inc. Announces Appointment of Kevin Sow Peng Teo as Chief Financial Officer
5. 3SBio Inc. To Present at the 19th Annual Piper Jaffray Health Care Conference
6. 3SBio Inc. Schedules 2007 Third Quarter Earnings Release On Tuesday, November 13, 2007
7. 3SBio Inc. to Hold Annual General Meeting
8. 3SBio Inc. to Present at the UBS Global Life Sciences Conference
9. 5AM Ventures Announces Expansion of Investment Team: Names Richard Ulevitch Venture Partner; Promotes Kevin Forrest and Andrew McMillan to Principal
10. Sunesis Pharmaceuticals Announces Milestone Payment from Inflammation Collaboration
11. Neuralstem Inc. Announces Strategic Investment by Korean CJ CheilJedang Corporation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/4/2015)... ... September 04, 2015 , ... November Research ... services and software tools to pharmaceutical and life sciences organizations, today announced the ... Mobile is a mobile data intake solution that enables field sales representatives, clinical ...
(Date:9/3/2015)...  Vermillion, Inc. (NASDAQ: VRML ), a bio-analytical ... Herbert Fritsche , Ph.D., the Lab Director of ... of the 2015 Abbott Award, given by the International ... to the field of basic or clinical oncology. Dr. ... in Zakopane, Poland . Prior ...
(Date:9/3/2015)... ... 03, 2015 , ... Park Systems announced that they will host ... 9am PST. The webinar will focus on the methods and materials for additive manufacturing ... manufacturing is a broad term that encompasses “addition or fusion” of materials to create ...
(Date:9/2/2015)... DUBLIN , Sept. 2, 2015 /PRNewswire/ ... has announced the addition of Jain PharmaBiotech,s ... Companies" to their offering. ... the pharmaceutical and biotechnology industries is anticipated. ... of drug development - from formulations for ...
Breaking Biology Technology:November Research Group’s PRIMO Mobile Goes Live at Allergan Japan 2Vermillion Announces Dr. Herbert Fritsche as Recipient of the 2015 Abbott Award from the International Society of Oncology and Biomarkers 2Park Systems Announces Webinar on 3D Printing and Additive Manufacturing for Nano-Scientists, Researchers in Nanotechnology and Engineers 2Park Systems Announces Webinar on 3D Printing and Additive Manufacturing for Nano-Scientists, Researchers in Nanotechnology and Engineers 3Park Systems Announces Webinar on 3D Printing and Additive Manufacturing for Nano-Scientists, Researchers in Nanotechnology and Engineers 4Global Nanobiotechnology Applications, Markets and Companies Report 2015-2024 2Global Nanobiotechnology Applications, Markets and Companies Report 2015-2024 3
... market, EDMONTON, Aug. 27 /PRNewswire/ - Small ... bring nanotechnology products to,world markets can now access ... centre in Edmonton,s Research Park., The Alberta ... supported by $11.5 million in total funding with,contributions ...
... to put auto-injectable ... supplies list, SILVER SPRING, Md., Aug. 27 A ... found that 72% of school,nurses have students with a known ... not provided the school with auto-injectable,epinephrine. Also known as adrenaline, ...
... relapse, with use of Gleevec after surgery are basis for FDA, EMEA, Swissmedic ... filings, - Historically, one ... ... therapeutic approaches to patients with rare diseases, EAST ...
Cached Biology Technology:New nanotechnology centre helps turn big ideas into real products 2New nanotechnology centre helps turn big ideas into real products 3Video: New Survey Shows Three in Four School Nurses Have Students at Risk for Severe Allergic Reactions Who Do Not Bring Auto-Injectable Epinephrine to School 2Video: New Survey Shows Three in Four School Nurses Have Students at Risk for Severe Allergic Reactions Who Do Not Bring Auto-Injectable Epinephrine to School 3Video: New Survey Shows Three in Four School Nurses Have Students at Risk for Severe Allergic Reactions Who Do Not Bring Auto-Injectable Epinephrine to School 4Gleevec Receives FDA Priority Review as First Therapy to Reduce Recurrence of Gastrointestinal Stromal Tumors After Surgery 2Gleevec Receives FDA Priority Review as First Therapy to Reduce Recurrence of Gastrointestinal Stromal Tumors After Surgery 3Gleevec Receives FDA Priority Review as First Therapy to Reduce Recurrence of Gastrointestinal Stromal Tumors After Surgery 4Gleevec Receives FDA Priority Review as First Therapy to Reduce Recurrence of Gastrointestinal Stromal Tumors After Surgery 5Gleevec Receives FDA Priority Review as First Therapy to Reduce Recurrence of Gastrointestinal Stromal Tumors After Surgery 6Gleevec Receives FDA Priority Review as First Therapy to Reduce Recurrence of Gastrointestinal Stromal Tumors After Surgery 7Gleevec Receives FDA Priority Review as First Therapy to Reduce Recurrence of Gastrointestinal Stromal Tumors After Surgery 8Gleevec Receives FDA Priority Review as First Therapy to Reduce Recurrence of Gastrointestinal Stromal Tumors After Surgery 9Gleevec Receives FDA Priority Review as First Therapy to Reduce Recurrence of Gastrointestinal Stromal Tumors After Surgery 10Gleevec Receives FDA Priority Review as First Therapy to Reduce Recurrence of Gastrointestinal Stromal Tumors After Surgery 11Gleevec Receives FDA Priority Review as First Therapy to Reduce Recurrence of Gastrointestinal Stromal Tumors After Surgery 12
(Date:8/6/2015)... CITY, Calif. , Aug. 6, 2015 /PRNewswire/ ... Valley) will visit Crossmatch ™ to learn ... networks and protect data. Crossmatch is a world ... whose technologies and expertise are helping federal agencies ... efficiency and security.   "The vast ...
(Date:8/5/2015)... Calif. , Aug. 5, 2015 The ... continuous growth in applications, penetration into newer sectors, and ... year. The global biosensors space has seen the entry ... the market so far. (Photo - ... & Sullivan, Analysis of the Global Biosensors Market ...
(Date:7/31/2015)... China , 31 de julio de 2015 /PRNewswire/ ... Genómica (ICG-10,  www.icg-10.org ) del 22 al 25 de ... . La conferencia celebra su décimo aniversario ... ha convertido en una de las reuniones anuales más ... y es una de las conferencias científicas más dinámicas, ...
Breaking Biology News(10 mins):Rep. Honda to Visit Crossmatch in Redwood City 2Innovative Biosensors Incite Use in Non-Traditional Applications 2Innovative Biosensors Incite Use in Non-Traditional Applications 3Innovative Biosensors Incite Use in Non-Traditional Applications 4La 10ª Conferencia Internacional sobre Genómica (ICG-10) comienza en octubre 2La 10ª Conferencia Internacional sobre Genómica (ICG-10) comienza en octubre 3
... technique for reprogramming human adult cells could greatly improve the ... in a range of therapeutic applications to repair or replace ... is published in the peer-reviewed journal Cellular Reprogramming , ... free online. Stem cells offer great promise ...
... available in French . , Eradicating smallpox was ... but new research shows initiatives of this kind are not ... think. McGill University Biologist Dr. Jonathan Davies explains that reducing ... is a far more effective and efficient strategy than trying ...
... found in both coconut oil and human breast milk ... thanks to a bioengineering graduate student from the UC San ... delivery system" published in the journal ACS Nano ... directly to skin-dwelling bacteria ( Propionibacterium acnes ) that cause ...
Cached Biology News:Novel strategy for generating induced pluripotent stem cells for clinical use is safe and efficient 2Trying to eradicate a disease is a waste of money: researcher 2Treat acne with coconut oil and nano-bombs 2
SCP-1 (P-17)...
Immunogen: Purified native p24 from strain IIIB. Storage: -20 C, Avoid Freeze/Thaw Cycles...
Biotin d anti-mouse Tim-1...
Mouse monoclonal [MLM544] to cardiac Myosin light chain 1 ( Abpromise for all tested applications). entrezGeneID: 4634 SwissProtID: P08590...
Biology Products: